Opko Health Inc. OPK shares are trading higher by $0.44 (5 percent) at $9.63 in Tuesday's session. The catalyst for the rally is the confirmation that the FDA has approved NDA for Rayaldee to treat certain symptoms of chronic kidney disease.
After a higher open, the issue immediately peaked at $9.99 and began to retreat. That high coincides with a trio of highs it made at the area in early June. The ensuing decline so far has found support ahead of the top end of Monday's range ($9.31) as the current low stands at $9.54.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.